Osteoporosis Therapy: Bone Modeling during Growth and Aging

Osteoporosis Therapy: Bone Modeling during Growth and Aging

Bibliographic Details
Main Authors:	Toshihiro Sugiyama, Hiromi Oda
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2017-03-01
Series:	Frontiers in Endocrinology
Subjects:	mechanical strain bone modeling osteoporosis romosozumab abaloparatide
Online Access:	http://journal.frontiersin.org/article/10.3389/fendo.2017.00046/full

Similar Items

Anabolic therapy for osteoporosis: update on efficacy and safety
by: Leonardo Bandeira, et al.
Published: (2022-12-01)

Pharmacological Therapy of Osteoporosis: What’s New?
by: Iolascon G, et al.
Published: (2020-03-01)

Romosozumab and blosozumab: alternative drugs of mechanical strain-related stimulus toward a cure for osteoporosis
by: Toshihiro eSugiyama, et al.
Published: (2015-04-01)

Sclerostin antibodies as novel anabolic therapy for osteoporosis
by: Elizaveta O. Mamedova, et al.
Published: (2019-04-01)

Profile of romosozumab and its potential in the management of osteoporosis
by: Lim SY, et al.
Published: (2017-04-01)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
by: Mingwei Hu, et al.
Published: (2023-07-01)

Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives
by: Lim SY, et al.
Published: (2022-12-01)

Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis
by: Pan Hong, et al.
Published: (2023-02-01)

Osteoporosis clinical practice guideline: romosozumab for treating severe osteoporosis – an update by the Egyptian Academy of Bone Health
by: Yasser El Miedany, et al.
Published: (2022-09-01)

Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study
by: Takeshi Mochizuki, et al.
Published: (2021-09-01)

Abaloparatide exhibits greater osteoanabolic response and higher cAMP stimulation and β‐arrestin recruitment than teriparatide
by: Karim Sahbani, et al.
Published: (2019-10-01)

Osteoporosis Improved by Romosozumab Therapy in a Patient With Type I Osteogenesis Imperfecta
by: Antara Dattagupta, MD, MEng, et al.
Published: (2023-11-01)

New Human Leukocyte Antigen (HLA) Antibody Formation and Creatinine Elevation With Abaloparatide in Kidney Transplant Recipient
by: Christine M. Swanson, et al.
Published: (2023-12-01)

Abaloparatide and the Spine: A Narrative Review
by: Thompson JC, et al.
Published: (2020-06-01)

Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS)
by: Annika Vestergaard Kvist, et al.
Published: (2021-04-01)

Abaloparatide Has the Same Catabolic Effects on Bones of Mice When Infused as PTH (1–34)
by: Carole Le Henaff, et al.
Published: (2023-02-01)

Osteoporosis Treatment with Anti-Sclerostin Antibodies—Mechanisms of Action and Clinical Application
by: Martina Rauner, et al.
Published: (2021-02-01)

Romosozumab in osteoporosis: yesterday, today and tomorrow
by: Dong Wu, et al.
Published: (2023-09-01)

Glucocorticoid-Induced Osteoporosis: The Potential Role of Romosozumab
by: Jacqueline So, et al.
Published: (2020-12-01)

Optimal Intermittent Administration Interval of Abaloparatide for Bone Morphogenetic Protein-Induced Bone Formation in a Rat Spinal Fusion Model
by: Tetsutaro Abe, et al.
Published: (2024-03-01)

Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)
by: Barbara C. Silva, et al.
Published: (2022-10-01)

Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report
by: Yoichi Kaneuchi, et al.
Published: (2022-12-01)

Real-world effects and adverse events of romosozumab in Japanese osteoporotic patients: A prospective cohort study
by: Tomonori Kobayakawa, et al.
Published: (2021-06-01)

Papel del Romosozumab en la práctica clínica a la luz de la evidencia
by: Alejandro Román-González, et al.
Published: (2022-01-01)

Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta‐analysis through a Grade Analysis of Evidence
by: Aixian Tian, et al.
Published: (2021-10-01)

Molecular Targeted Therapy for the Bone Loss Secondary to Pyogenic Spondylodiscitis Using Medications for Osteoporosis: A Literature Review
by: Takashi Ohnishi, et al.
Published: (2021-04-01)

The Efficacy of PTH and Abaloparatide to Counteract Immobilization-Induced Osteopenia Is in General Similar
by: Mikkel Bo Brent, et al.
Published: (2020-10-01)

Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
by: Ki-Hyun Baek, et al.
Published: (2021-02-01)

The use of abaloparatide to treat nonunion following dorsal closing wedge osteotomy for Freiberg's disease: A case report
by: Jessica A. Nelson, et al.
Published: (2021-12-01)

Comparison of the Efficacy of Romosozumab and Teriparatide for the Management of Osteoporotic Vertebral Compression Fractures
by: Danbi Park, et al.
Published: (2023-12-01)

Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient
by: Bhanvi Ramchandani, et al.
Published: (2024-03-01)

Bone turnover markers, use in osteoporosis
by: Astrid Kamilla Stunes, et al.
Published: (2013-05-01)

Estimation of optimal frequencies for electrical impedance-based diagnosis of osteoporosis based on numerical modeling of cancellous bone tissue
by: Goodarzi Reza, et al.
Published: (2016-12-01)

The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts
by: Karina E. Pigeaud, et al.
Published: (2023-04-01)

Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report
by: Masafumi Kashii, et al.
Published: (2020-12-01)

Osteoporosis : adakah anda dalam bahaya? /
by: 526551 Ima Nirwana Soelaiman
Published: (2002)

Advancement in the Treatment of Osteoporosis and the Effects on Bone Healing
by: Yevgeniya Kushchayeva, et al.
Published: (2022-12-01)

Measurement of Bone Mineral Density in Diagnosis of Osteoporosis
by: Seher Kocaoğlu, et al.
Published: (2003-12-01)

The Effects of Risedronate Therapy Combined With Vitamin D and Calcium on Biochemical Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporosis
by: Hüsniye Koç, et al.
Published: (2004-12-01)

Editorial: Bone aging and osteoporosis: recent evidence focusing on plant-based natural products
by: Ling-Feng Zeng, et al.
Published: (2024-03-01)